SI2796466T1 - Molekule humaniziranih protiteles specifične za il-31 - Google Patents
Molekule humaniziranih protiteles specifične za il-31 Download PDFInfo
- Publication number
- SI2796466T1 SI2796466T1 SI200831897T SI200831897T SI2796466T1 SI 2796466 T1 SI2796466 T1 SI 2796466T1 SI 200831897 T SI200831897 T SI 200831897T SI 200831897 T SI200831897 T SI 200831897T SI 2796466 T1 SI2796466 T1 SI 2796466T1
- Authority
- SI
- Slovenia
- Prior art keywords
- seq
- amino acid
- binding fragment
- antigen
- isolated monoclonal
- Prior art date
Links
- 101710181613 Interleukin-31 Proteins 0.000 title claims abstract 5
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 150000001413 amino acids Chemical group 0.000 claims 6
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 201000009053 Neurodermatitis Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 208000017940 prurigo nodularis Diseases 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000045345 human IL31 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 238000011577 humanized mouse model Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000670 limiting effect Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 230000001823 pruritic effect Effects 0.000 abstract 1
- 230000001603 reducing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (8)
- MOLEKULE HUMANIZIRANIH PROTITELES SPECIFIČNE ZA IL-31 EP 2 796 466 B1 PATENTNI ZAHTEVKI1. Izolirano monoklonsko protitelo ali njegov antigen vezavni fragment, ki se specifično veže na humani IL-31, ki obsega humanizirano variabilno težkoverižno domeno in humanizirano variabilno lahkoverižno domeno, kjer humanizirana variabilna težkoverižna domena obsega CDR1, CDR2 in CDR3, ki sestoji iz aminokislinskega zaporedja SEQ ID NOs: 1, 2 in 3, posamezno, in imajo okvirni predeli FR1, FR2, FR3 in FR4, aminokislinsko zaporedje, ki je vsaj 90% identično aminokislinskemu zaporedju SEQ ID NO: 12 (FR1), SEQ ID NO: 13 (FR2), SEQ ID NO: 14 (FR3) in SEQ ID NO: 15 (FR4); in kjer humanizirana variabilna lahkoverižna domena obsega CDR1, CDR2 in CDR3, ki sestoji iz aminokislinskega zaporedja SEQ ID NOs: 5, 6 in 7, in imajo okvirni predeli FR5, FR6, FR7 in FR8, aminokislinsko zaporedje, ki je vsaj 90% identično aminokislinskemu zaporedju SEQ ID NO: 17 (FR5), SEQ ID NO: 18 (FR6), SEQ ID NO: 19 (FR7) in SEQ ID NO: 20 (FR8); kjer je aminokislinski ostanek na položaju 29 od SEQ ID NO: 12 (FRI) leucin, aminokislinski ostanek na položaju 8 od SEQ ID NO: 14 (FR3) je lizin, aminokislinski ostanek na položaju 32 od SEQ ID NO: 14 (FR3) je fenilalanin in aminokislinski ostanek na položaju 15 od SEQ ID NO: 19 (FR7) je tirozin.
- 2. Izolirani monoklonski antigen-vezavni fragment po zahtevku 1, kjer antigen vezavni fragment nadalje obsega domeno Fc.
- 3. Izolirano monoklonsko protitelo ali njegov antigen vezavni fragment po zahtevku 1 ali 2, kjer protitelo ali antigen vezavni fragment nadalje obsega konstantno težkoverižno domeno imunoglobulina, izbrano izmed skupine, ki jo sestavljajo: a) konstantna domena humanega IgGI; b) konstantna domena humanega lgG2; c) konstantna domena humanega lgG3; in d) konstantna domena humanega lgG4.
- 4. Izolirano monoklonsko protitelo ali njegov antigen vezavni fragment po zahtevku 3, kjer je konstantna težkoverižna domena imunoglobulina konstantna domena humanega lgG4.
- 5. Izolirano monoklonsko protitelo ali njegov antigen vezavni fragment, po zahtevku 4, kjer ima konstantna domena humanega lgG4 serin za proline mutacijo na položaju 241, kot je določeno po Kabatu.
- 6. Uporaba izoliranega monoklonskega protitelesa ali antigen vezavnega fragmenta, po kateremkoli od zahtevkov 1-5, za izdelavo zdravila za zdravljenje atopičnega dermatitisa, dermatitisa, prurigo nodularisa, ekcema, pruritusa, vitiliga, alopecia aerata, akne rozacea, akne vulgaris, bulozni pemfigoid ali kontaktnega dermatitisa.
- 7. Izolirano monoklonsko protitelo ali antigen vezavni fragment, po kateremkoli od zahtevkov 1-5 za uporabo pri zdravljenju atopičnega dermatitisa, dermatitisa, prurigo nodularisa, ekcema, pruritusa, vitiliga, alopecia aerate, akne rozacee, akne vulgaris, buloznega pemfigoida ali kontaktnega dermatitisa.
- 8. Uporaba po zahtevku 6 ali izolirano monoklonsko protitelo ali antigen vezavni fragment, za uporabo po zahtevku 7, v kombinaciji s farmacevtsko sprejemljivim nosilcem.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1236207P | 2007-12-07 | 2007-12-07 | |
| EP14175301.2A EP2796466B1 (en) | 2007-12-07 | 2008-12-08 | Humanized antibody molecules specific for IL-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2796466T1 true SI2796466T1 (sl) | 2018-01-31 |
Family
ID=40347963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200831897T SI2796466T1 (sl) | 2007-12-07 | 2008-12-08 | Molekule humaniziranih protiteles specifične za il-31 |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US8470979B2 (sl) |
| EP (3) | EP2796466B1 (sl) |
| JP (2) | JP5744522B2 (sl) |
| KR (1) | KR101603109B1 (sl) |
| CN (1) | CN101970488B (sl) |
| AU (1) | AU2008333131B2 (sl) |
| BR (1) | BRPI0820099A2 (sl) |
| CA (1) | CA2708251C (sl) |
| CY (1) | CY1120412T1 (sl) |
| DK (1) | DK2796466T3 (sl) |
| EA (1) | EA020457B1 (sl) |
| ES (2) | ES2570853T3 (sl) |
| HK (2) | HK1154020A1 (sl) |
| HR (1) | HRP20180252T1 (sl) |
| HU (1) | HUE036548T2 (sl) |
| IL (1) | IL206147A (sl) |
| LT (1) | LT2796466T (sl) |
| ME (1) | ME03057B (sl) |
| NO (1) | NO2796466T3 (sl) |
| PL (1) | PL2796466T3 (sl) |
| PT (1) | PT2796466T (sl) |
| RS (1) | RS56930B1 (sl) |
| SI (1) | SI2796466T1 (sl) |
| TR (1) | TR201802202T4 (sl) |
| WO (1) | WO2009071696A2 (sl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2230299T3 (da) | 2002-01-18 | 2012-03-26 | Zymogenetics Inc | Hidtil ukendt cytokin ZCYTOR17-ligand |
| WO2006088955A2 (en) * | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| ES2561628T3 (es) * | 2005-05-06 | 2016-02-29 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y métodos de uso |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| CA2633439A1 (en) | 2006-01-10 | 2007-11-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| CA2660175C (en) | 2006-09-01 | 2015-05-12 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| DK2796466T3 (en) | 2007-12-07 | 2018-02-05 | Zymogenetics Inc | HUMANIZED ANTIBODY MOLECULE SPECIFIC TO IL-31 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| HUE046508T2 (hu) * | 2012-10-11 | 2020-03-30 | Nerre Therapeutics Ltd | Orvepitant krónikus viszketés kezelésére |
| SG11201508829QA (en) | 2013-05-30 | 2015-12-30 | Biogen Ma Inc | Oncostatin m receptor antigen binding proteins |
| AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| AR102333A1 (es) * | 2014-08-19 | 2017-02-22 | Regeneron Pharma | Selectividad eficiente de proteínas recombinadas |
| KR102641898B1 (ko) | 2015-04-14 | 2024-02-27 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
| BR112017022101A2 (pt) | 2015-04-14 | 2018-07-31 | Chugai Seiyaku Kabushiki Kaisha | composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo |
| US9862760B2 (en) * | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| ES2823173T3 (es) | 2016-01-27 | 2021-05-06 | Just Biotherapeutics Inc | Promotor híbrido y usos del mismo |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| EP3717510A2 (en) | 2017-12-01 | 2020-10-07 | Novartis AG | Polyomavirus neutralizing antibodies |
| BR112020017703A2 (pt) | 2018-03-16 | 2021-03-09 | Zoetis Services Llc | Anticorpos monoclonais de interleucina-31 para uso veterinário |
| BR112020017715A2 (pt) | 2018-03-16 | 2020-12-29 | Zoetis Services Llc | Vacinas de peptídeo contra interleucina-31 |
| FR3084365B1 (fr) * | 2018-07-27 | 2020-10-23 | Cisbio Bioassays | Anticorps a domaine unique qui se lient a la proteine g alpha |
| WO2021100794A1 (ja) * | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
| JP6799831B1 (ja) | 2020-09-01 | 2020-12-16 | 中外製薬株式会社 | Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
| IL303135A (en) * | 2020-12-23 | 2023-07-01 | Numab Therapeutics AG | Antibody variable domains that bind IL-4R |
| EP4019546A1 (en) * | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Antibody variable domains that bind il-31 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US459293A (en) | 1891-09-08 | Horse-checking device | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4054646A (en) | 1973-07-30 | 1977-10-18 | General Electric | Method and apparatus for detection of antibodies and antigens |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| EP0232262A4 (en) | 1985-08-15 | 1989-09-19 | Stauffer Chemical Co | MICROORGANISM PRODUCING TRYPTOPHANE. |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
| US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| NZ229700A (en) | 1988-06-24 | 1993-01-27 | Dow Chemical Co | Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments |
| US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| ZA894792B (en) | 1988-06-24 | 1991-04-24 | Dow Chemical Co | Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates |
| US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
| US5078997A (en) | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| ATE143509T1 (de) | 1990-06-21 | 1996-10-15 | Honeywell Inc | Auf variablem horizont basierende adaptive steuerung mit mitteln zur minimierung der betriebskosten |
| GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| CA2074825C (en) | 1990-12-14 | 2005-04-12 | Daniel J. Capon | Chimeric chains for receptor-associated signal transduction pathways |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5492841A (en) | 1994-02-18 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Quaternary ammonium immunogenic conjugates and immunoassay reagents |
| US5783672A (en) | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
| EP0770135A1 (en) | 1994-07-29 | 1997-05-02 | Smithkline Beecham Plc | Novel compounds |
| CA2209124C (en) | 1994-12-29 | 2010-03-23 | Chugai Seiyaku Kabushiki Kaisha | Antitumor agent effect enhancer containing il-6 antagonist |
| EP1323346B1 (en) | 1995-01-17 | 2006-06-28 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US5792850A (en) | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
| DE19623207A1 (de) * | 1996-06-11 | 1997-12-18 | Bayer Ag | Imidazolderivate |
| WO2002000690A2 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US20020034507A1 (en) | 1997-02-28 | 2002-03-21 | Yasuo Koishihara | Inhibitor of lymphocyte activation |
| EP2135953B1 (en) | 1999-06-02 | 2014-04-23 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor protein, Nr. 10 |
| AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030096339A1 (en) | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
| AU2001273032A1 (en) | 2000-06-26 | 2002-01-08 | Zymogenetics Inc. | Cytokine receptor zcytor17 |
| AU2001273150A1 (en) | 2000-07-20 | 2002-02-05 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2005507632A (ja) | 2000-10-06 | 2005-03-24 | イミュネックス・コーポレーション | ヘマトポエチン受容体、ｈｐｒ１およびｈｐｒ２ |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| WO2002077230A1 (fr) | 2001-03-26 | 2002-10-03 | Chugai Seiyaku Kabushiki Kaisha | Variants d'epissage nr10 |
| EP1461428B1 (en) | 2001-12-03 | 2012-03-21 | Alexion Pharmaceuticals, Inc. | Method for producing hybrid antibodies |
| DK2230299T3 (da) | 2002-01-18 | 2012-03-26 | Zymogenetics Inc | Hidtil ukendt cytokin ZCYTOR17-ligand |
| EP2840089A1 (en) | 2002-01-18 | 2015-02-25 | ZymoGenetics, Inc. | Cytokine receptor zcytor17 multimers |
| DK1485477T3 (da) | 2002-02-25 | 2009-08-10 | Genentech Inc | Hidtil ukendt type-1-cytokinreceptor GLM-R |
| WO2003106655A2 (en) * | 2002-06-18 | 2003-12-24 | The University Of Akron | Fibrous protein-immobilization systems |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| DE602004012424T2 (de) | 2003-08-07 | 2009-04-30 | Zymogenetics, Inc., Seattle | Homogene herstellungen von il-29 |
| RU2007108716A (ru) | 2004-09-10 | 2008-10-20 | Вайет (Us) | Гуманизированные антитела к антигену 5т4 и конъюгаты гуманизированного антитела к антигену 5т4 с калихеамицином |
| AR051836A1 (es) | 2004-11-30 | 2007-02-14 | Centocor Inc | Antagonistas de receptor 3 simil toll metodos y usos |
| WO2006081573A2 (en) | 2005-01-28 | 2006-08-03 | Zymogenetics, Inc. | Homogeneous preparations of il-31 |
| WO2006088955A2 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| EP1858924A1 (en) | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| ES2561628T3 (es) | 2005-05-06 | 2016-02-29 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y métodos de uso |
| US8101183B2 (en) * | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| CA2633439A1 (en) | 2006-01-10 | 2007-11-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| CA2660175C (en) | 2006-09-01 | 2015-05-12 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| WO2008086505A2 (en) | 2007-01-10 | 2008-07-17 | Zymogenetics, Inc. | Methods of using il-31 to treat airway hyper-responsiveness and asthma |
| DK2796466T3 (en) * | 2007-12-07 | 2018-02-05 | Zymogenetics Inc | HUMANIZED ANTIBODY MOLECULE SPECIFIC TO IL-31 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
-
2008
- 2008-12-08 DK DK14175301.2T patent/DK2796466T3/en active
- 2008-12-08 EP EP14175301.2A patent/EP2796466B1/en active Active
- 2008-12-08 EA EA201070695A patent/EA020457B1/ru not_active IP Right Cessation
- 2008-12-08 BR BRPI0820099-8A patent/BRPI0820099A2/pt not_active Application Discontinuation
- 2008-12-08 HU HUE14175301A patent/HUE036548T2/hu unknown
- 2008-12-08 KR KR1020107012559A patent/KR101603109B1/ko active IP Right Grant
- 2008-12-08 ES ES12161272T patent/ES2570853T3/es active Active
- 2008-12-08 NO NO14175301A patent/NO2796466T3/no unknown
- 2008-12-08 CA CA2708251A patent/CA2708251C/en active Active
- 2008-12-08 PT PT141753012T patent/PT2796466T/pt unknown
- 2008-12-08 ME MEP-2018-41A patent/ME03057B/me unknown
- 2008-12-08 ES ES14175301.2T patent/ES2660036T3/es active Active
- 2008-12-08 US US12/329,820 patent/US8470979B2/en active Active
- 2008-12-08 WO PCT/EP2008/067024 patent/WO2009071696A2/en active Application Filing
- 2008-12-08 CN CN200880119654.9A patent/CN101970488B/zh active Active
- 2008-12-08 SI SI200831897T patent/SI2796466T1/sl unknown
- 2008-12-08 PL PL14175301T patent/PL2796466T3/pl unknown
- 2008-12-08 LT LTEP14175301.2T patent/LT2796466T/lt unknown
- 2008-12-08 RS RS20180194A patent/RS56930B1/sr unknown
- 2008-12-08 JP JP2010536489A patent/JP5744522B2/ja active Active
- 2008-12-08 AU AU2008333131A patent/AU2008333131B2/en not_active Ceased
- 2008-12-08 EP EP08856113A patent/EP2215120A2/en not_active Withdrawn
- 2008-12-08 TR TR2018/02202T patent/TR201802202T4/tr unknown
- 2008-12-08 EP EP12161272.5A patent/EP2471817B1/en active Active
-
2010
- 2010-06-03 IL IL206147A patent/IL206147A/en active IP Right Grant
-
2011
- 2011-08-08 HK HK11108257.8A patent/HK1154020A1/xx not_active IP Right Cessation
-
2012
- 2012-10-04 HK HK12109760.5A patent/HK1169127A1/zh not_active IP Right Cessation
-
2013
- 2013-06-03 US US13/908,436 patent/US8685669B2/en active Active
-
2014
- 2014-02-07 US US14/174,870 patent/US9005921B2/en active Active
- 2014-10-31 JP JP2014223129A patent/JP5852210B2/ja active Active
-
2015
- 2015-03-12 US US14/645,769 patent/US9416184B2/en active Active
-
2016
- 2016-07-13 US US15/208,990 patent/US9738715B2/en active Active
-
2017
- 2017-07-12 US US15/648,252 patent/US9982044B2/en active Active
-
2018
- 2018-01-26 CY CY20181100106T patent/CY1120412T1/el unknown
- 2018-02-09 HR HRP20180252TT patent/HRP20180252T1/hr unknown
- 2018-04-26 US US15/963,497 patent/US10640559B2/en active Active
-
2020
- 2020-03-30 US US16/834,607 patent/US11542327B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2796466T1 (sl) | Molekule humaniziranih protiteles specifične za il-31 | |
| HRP20191083T1 (hr) | Molekule antitijela za tim-3 i njihove upotrebe | |
| ES2605945T3 (es) | Anticuerpos de unión a Tweak | |
| HRP20211058T1 (hr) | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 | |
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| HRP20181069T1 (hr) | Antagonistička protutijela na il-17 | |
| IL259927B1 (en) | Humanized antibodies against cd73 | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| HRP20210892T1 (hr) | Terapijska uporaba specifičnog liganda u bolestima povezanim s msrv | |
| AR035581A1 (es) | Anticuerpos para il-1beta humana | |
| HRP20220405T1 (hr) | Protutijela protiv ngf i njihova upotreba | |
| GEP20074222B (en) | Antibodies to cd40 | |
| PE20081185A1 (es) | Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden | |
| WO2007103470A3 (en) | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
| NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
| PE20121689A1 (es) | Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos | |
| RS51334B (en) | CD20 Antibodies with Increased Binding Affinity for FC RECEPTOR AND EFFECTORY FUNCTION | |
| WO2007103469A3 (en) | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
| JP2020514277A5 (sl) | ||
| HRP20210604T1 (hr) | Humanizirano anti-hmgb1 antitijelo ili njegov fragment koji veže antigen |